Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022139539 - COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION

Publication Number WO/2022/139539
Publication Date 30.06.2022
International Application No. PCT/KR2021/019796
International Filing Date 24.12.2021
IPC
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • 아주대학교산학협력단 AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION [KR]/[KR]
Inventors
  • 우현구 WOO, Hyun Goo
  • 사마소드 SHAH, Masaud
  • 문승욱 MOON, Sung Ung
Agents
  • 특허법인 태백 TAEBAEK INTELLECTUAL PROPERTY LAW FIRM
Priority Data
10-2020-018348824.12.2020KR
10-2021-007739815.06.2021KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION
(FR) COMPOSITION POUR PRÉVENIR OU TRAITER UNE INFECTION PAR SARS-COV-2
(KO) SARS-CoV-2 감염증에 대한 예방 또는 치료용 조성물
Abstract
(EN) The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).
(FR) La présente invention concerne une composition pour prévenir ou traiter une infection par SARS-CoV-2. CSNP1, CSNP2, CSNP3 et CSNP4 se lient au récepteur du domaine de liaison (RBD) de la protéine de spicule du SARS-CoV-2 pour inhiber l'interaction de la protéine de spicule du SARS-CoV-2 avec ACE2, interférant ainsi avec le mécanisme au moyen duquel le SRAS-CoV-2 pénètre les cellules ou échappe à l'immunité. Ainsi, l'invention concerne une composition comprenant CSNP1, CSNP2, CSNP3 ou CSNP4 en tant que principe actif servant d'agent pharmaceutique pour la prévention ou le traitement d'une infection par SARS-CoV-2 (COVID19).
(KO) 본 발명은 SARS-CoV-2 감염증에 대한 예방 또는 치료용 조성물에 관한 것으로, CSNP1, CSNP2, CSNP3 및 CSNP4는 SARS-CoV-2의 스파이스 단백질의 RBD(receptor binding domain)에 결합하여 SARS-CoV-2의 스파이스 단백질과 ACE2의 상호작용을 억제함으로써, SARS-CoV-2가 세포에 진입하거나 면역 회피하는 메커니즘을 방해하기 때문에, CSNP1, CSNP2, CSNP3 또는 CSNP4를 유효성분으로 포함하는 조성물을 SARS-CoV-2 감염증(COVID19)의 예방 또는 치료를 위한 약제로 제공된다.
Latest bibliographic data on file with the International Bureau